BRAF and acral lentiginous melanoma: Figure 4 shows the results of the survival curves. Patients with BRAF V600E-positive acral melanoma had significantly shorter melanoma-specific survival (MSS) than those with BRAF V600E-negative melanoma (p = 0.0283, log-rank test; 5-year MSS, 56.1% and 83.9%, respectively; Figure 4A). In contrast, BRAF V600E positivity was not a significant prognostic factor for disease-free survival (DFS) in our cohort (p = 0.3867, log-rank test; Figure 4B).